NANicoletta Pia Ardò

Nicoletta Pia Ardò

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nicoletta Pia Ardò has a total of 79 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Expression Analysis of let-7a-5p and miR-21-3p in Extracellular Vesicles Derived from Serum of NSCLC Patients

    by Dian Jamel Salih, Katrin S. Reiners, Domenico Loizzi, Nicoletta Pia Ardò, Teresa Antonia Santantonio, Francesco Sollitto, Gunther Hartmann

    Background/Objectives: Despite the significant advancements made in the diagnosis of lung cancer, the traditional diagnostic methods remain limited because they are often invasive, expensive, and not suitable for regular screening, creating a need for more accessible and non-invasive alternatives. In this context, the analysis of miRNAs in EVs and free circulating microRNA may be used as liquid biopsies in lung cancer to identify individuals at risk. This study aimed to compare miRNA profiles in the serum and EVs derived from lung cancer patients by focusing on Let-7a-5p and miR-21-3p. Materials and Methods: Serum and EVs were isolated from lung cancer patients and healthy controls. EVs were characterized using nanoparticle tracking analysis, electron microscopy, and Western blotting for surface markers (CD63, CD81, TSG101). Total miRNA levels were quantified in the serum and EVs, and specific miRNAs (hsa-let-7a-5p and hsa-miR-21-3p) were analyzed using RT-qPCR. Statistical analysis evaluated miRNA expression across clinicopathological features, including age, gender, smoking status, tumor stage, cancer type, and EGFR mutation status. Results: Total miRNA levels were significantly enriched in EVs compared to the serum. Let-7a-5p was downregulated in EVs from patients with advanced-stage lung cancer (Stage III–IV) compared to those with early-stage cancer and controls (p < 0.05), while no differences were observed in the serum. Conversely, miR-21-3p was significantly upregulated in EVs and serum from advanced-stage patients (p < 0.01) and in adenocarcinoma compared to squamous cell carcinoma (p < 0.05). No significant differences were observed for age, gender, or smoking status. Conclusions: Our findings highlight the differential expression of miRNAs in EVs and the serum, emphasizing the diagnostic potential of EV-associated Let-7a-5p and miR-21-3p in lung cancer. These results suggest that EVs are a more robust source for miRNA biomarkers compared to the serum.


  • Open Access

    Does Cannabis Smoke Cause Interstitial Lung Disease?

    by Mario Bisconti, Paola Martucci, Adele Minutillo, Alessandra Palma Modoni, Raffaella Giacobbe, Maria Concetta Rotolo, Francesco Sollitto, Domenico Loizzi, Nicoletta Pia Ardò, Senia Trabucco, et al.

    Background/Objectives: The correlation between drugs and interstitial lung disease (ILD) is reported, but the presence of the substances of abuse in the lung as a cause of disease has never been proved. In this observational study, our aim was to evaluate a possible correlation between ILD radiological findings and cannabinoids presence in broncho-alveolar lavage (BAL) or in resected lung tissue in patients with a history of cannabis smoke. Methods: Data of patients with ILD chest CT scan findings and history of drug use, submitted to BAL (Group 1), or to lung apex removal for pneumothorax (Group 2), were retrospectively collected. In both groups, drug presence was investigated. A subgroup of Group 1 was checked for the concomitant presence in blood. Fisher’s test was used to study the association between the detection of the drug and ILD. Results: In Group 1, cannabinoids were present in 12/26 (46.2%) BAL samples. ILD emerged on chest CT in 75% of the cannabinoid-positive and in 20% of the cannabinoid-negative BAL samples (p = 0.0299). In the subgroup, the patients who tested positive for cannabinoids/cocaine on BAL were 55.6%; 0% were positive only on blood (p = 0.0294). In Group 2, cannabinoids were present in 10/15 (66.7%) specimens. ILD was evident, respectively, in 40% and in 0% of the patients with cannabinoid-positive and cannabinoid-negative surgical specimens (p = 0.2308). Conclusions: The prevalence of ILD in patients with cannabinoid-positive BAL and in those with cannabinoid-positive surgical specimens suggests that ILD could be caused by cannabis smoke. The non-concomitant presence of substances in BAL and in blood advocates the diagnostic usefulness of searching for the drug in the target organ.

  • Surgical resection of Masaoka stage III thymic epithelial tumours with great vessels involvement: a retrospective multicentric analysis from the European Society of Thoracic Surgeons thymic database

    by Paolo Mendogni, Alper Toker, Bernhard Moser, Florentino Hernando Trancho, Clemens Aigner, Ivan Gomes Bravio, Nuria Maria Novoa, Laureano Molins, Lorena Costardi, Luca Voltolini, et al.

    OBJECTIVES: The aim of this study was to analyse the outcomes of an international cohort of patients affected by Masaoka stage III thymic epithelial tumours with vascular involvement and treated by surgery. METHODS: Study design was the observational multicentre retrospective cohort study. Data were extracted from the European Society of Thoracic Surgeons thymic database; additional variables were collected. Inclusion criteria were as follows: stage III (Masaoka–Koga) thymic epithelial tumours; surgery with radical intention; clinical or pathological great vessels involvement; and radiologically suspected or diagnosed intraoperatively. Outcome items were analysed. RESULTS: Sixty-five patients submitted to surgery from 2001 to 2017 fulfilled inclusion criteria. Thymoma and thymic carcinoma patients did not differ for demographics and clinical characteristics. The majority of great vessel treated were superior vena cava or innominate veins (72.3%). Eleven patients (16.9%) had postoperative cardiopulmonary complications; vascular stenosis was observed in 3 patients (4.6%). The multivariable Cox analysis for disease-free survival showed an increased hazard of recurrence for thymic carcinoma (hazard ratio = 3.59; 95% confidence interval: 1.66–7.78, P = 0.001). The 1-, 3-, 5- and 10-year overall survival rates were 0.86, 0.84, 0.81, and 0.53, respectively. There was no significant difference in overall survival according to resection status or between thymoma and thimic carcinoma. The univariable Cox regression model did not show an increased hazard of death for myasthenic patients considering all resection status and for patients who received neoadjuvant therapy. CONCLUSIONS: We observed that clinical outcomes of patients treated for stage III thymic epithelial tumours with vascular involvement are satisfactory suggesting to increase the confidence in dealing with these complex surgeries. Complete resection should be achieved, even though extensive vascular reconstructions are required.


  • Open Access

    Exhaled Breath Temperature Home Monitoring to Detect NSCLC Relapse: Results from a Pilot Study

    by Giovanna Elisiana Carpagnano, Todor A. Popov, Giulia Scioscia, Nicoletta Pia Ardò, Donato Lacedonia, Mario Malerba, Pasquale Tondo, Piera Soccio, Domenico Loizzi, Maria Pia Foschino Barbaro, et al.

    Background. Exhaled breath temperature (EBT) has been shown to reflect airway inflammation as well as increased vascularization, both involved in the pathogenesis of lung cancer. The aim of this study was to look for evidence that continuous EBT monitoring by such a device may help the early detection of relapse of lung cancer in patients with NSCLC who have been subjected to surgery with radical intent. Case Series. We included 11 subjects, who had been subjected to lung resection with radical intent for NSCLC in a prospective observational study. All patients received individual devices for EBT measurement and used them daily for 24 months after surgery. Subjects were also followed up by means of regular standard‐of‐care clinical and radiologic monitoring for lung cancer at four intervals separated by 6 months (T0, T1, T2, T3, and T4). In 5 patients, relapse of lung cancer was documented by means of lung biopsies. All of them recorded an elevation of their EBT at least one‐time interval (T1), corresponding to 6 months, before the relapse was diagnosed at T4. The individual EBT graphs over time differed among these patients, and their mean EBT variability increased by +4% towards the end of 24 months of monitoring. By contrast, patients without a relapse did not document an elevation of their EBT and their variability decreased by ‐1.4%. Conclusions. Our pilot study provided evidence that continuous EBT monitoring can help in the early detection of lung cancer relapse.


  • Open Access

    Thoracoscopic pleurodesis using talc poudrage versus cytotoxic drug in malignant pleural effusion: narrative review

    by Domenico Loizzi, Francesco Sollitto, Michele Piazzolla, Nicoletta Pia Ardò

    Malignant pleural effusion (MPE) indicates incurable cancer with a variable prognosis, from 4 to 12 months. Definitive control of effusion with pleurodesis should be undertaken in all patients with an expandable lung who are likely to require frequent drainages and with an expected survival greater than 3 months. Presently, talc is the most commonly used pleurodesis agent. It is inexpensive and readily available worldwide. Its superiority over alternative compounds has been suggested by more than one meta-analysis; thus, it is the agent of choice in the international guidelines. Talc is highly effective, with success rates from 80% to 95%, relative to the dose, number of administrations and patient’s metabolic and nutritional conditions, with acceptable side effects and risks in a patient with a modest life expectancy. Other substances used are tetracyclines (doxycycline, minocycline), bleomycin, nitrogen mustards, quinacrine, Corynebacterium parvum, interferon (IFN), methylprednisolone, doxorubicin, cisplatin, cytarabine, etoposide, fluorouracil, mitomycin C, gold- and phosphorus-radioactive isotopes, alcohol, povidone-iodine and silver nitrate. Talc remains the most effective sclerosant available for pleurodesis. There are no comparative studies showing the superiority of other substances to talc. Talc poudrage is highly effective, at least equivalent to talc slurry, with possible increased efficacy in certain disease subgroups. The lack of comparative randomized trials, different eligibility criteria and heterogeneity of the study populations do not help scientists determine the standards concerning the type of substance to be used, indications, and methods.


  • Extrapleural pneumonectomy in atypical mycobacteriosis: the modern use of "Sarot procedure"

    by Francesco Sollitto, Nicoletta P. Ardò, Roberto De Bellis, Rita D. Marasco, Domenico Loizzi

  • Ambulation for enhanced recovery in thoracic surgery: how far can we walk?

    by Nicoletta Pia Ardò, Domenico Loizzi, Francesco Sollitto

    Ambulation for enhanced recovery in thoracic surgery: how far can we walk?

  • Enhanced recovery pathways in thoracic surgery from Italian VATS group: nursing care program

    by Nicoletta Pia Ardò, Domenico Loizzi, Silvana Panariti, Ivana Piccinin, Francesco Sollitto

    Enhanced recovery after surgery (ERAS) is an interprofessional program that can lead to hastened patient recovery and reduced time in hospital. Nursing staff play a key role in the implementation of enhanced recovery protocols. This issue focalizes the role of nurses in ERAS program for patients submitted to Thoracic Surgery, in particular for cases of major lung resection performed by a minimally invasive surgical approach (VATS, video assisted thoracic surgery).


    • 1 July 2014
      • Vol. 35, 122-5

    Comparison of two surgical approaches for the treatment of primary spontaneous pneumothorax*.

    by N P Ardò, D Loizzi, A De Palma, D Caporale, R De Bellis, F Cialdella, S Tango, V Simone, F Sollitto

    The authors report a retrospective study on surgical treatment of primary spontaneous pneumothorax (PSP). Surgical approaches by Videoassisted axillary mini-thoracothomy (VAMT) and three-port VATS (t-VATS) are compared. Mean post-operative stay (MPS) and ipsilateral recurrence rate (IRR) are assessed. Secondary endpoints were about complications, early post-operative pain and long term neurologic symptoms. From January 2009 to December 2011 we consecutively observed 85 cases of PSP. Treatment was represented by surgery in 52 patients: the approach was by VAMT in 39 instances and t-VATS in 13. Median follow up was 30 months. Patients submitted to surgery had a MPS of 6.62 ± 1.5 days for VAMT and 6.69 ± 3.4 days for t-VATS (p=0,94). The IRR was 0% in both surgical approaches, comparing to 7,2% for the group of patients treated by simple drainage. Complications were observed in VAMT group: 2 conversions to thoracothomy for technical difficulties (extensive pleural adherences) and one case of re-thoracothomy for hemothorax. Mean Visual Analogic Scale (VAS) score for early post-operative pain was: 2.10±0.71 for VAMT and 1.92±0.64 for t-VATS, p=0.42 at t-student test. Paresthesia complain rate was 33.3% (VAMT) vs 30.7% (t-VATS) for moderate symptoms (p=0.72 at chi square test). The remaining patients complained only slight symptoms or no symptoms at all. Our experience suggested that both surgical approaches to PSP are safe and effective. No differences were found for early post-operative pain and long term paresthesia rate, between the two approaches. No recurrence occurred during follow up.